Research programme: cannabinoid extract therapeutics - Easton Pharmaceuticals

Drug Profile

Research programme: cannabinoid extract therapeutics - Easton Pharmaceuticals

Alternative Names: Medicinal marijuana - Easton Pharmaceuticals

Latest Information Update: 07 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Easton Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 28 Mar 2014 Easton Pharmaceuticals and a undisclosed company agree to co-develop cannabinoid extract therapeutics in USA
  • 25 Mar 2014 Early research in Undefined indication in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top